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Background: Type 2 diabetes mellitus (T2DM) affects 25.8 million individuals in the United States and exerts a
substantial economic burden on patients, health care systems, and society. Few studies have categorized costs and
resource use at the patient level. The goals of this study were to assess predictors of being a high-cost (HC) patient
and compare HC T2DM patients with not high-cost (NHC) T2DM patients.
Methods: Using managed care administrative claims data, patients with two or more T2DM diagnoses between
2005 and 2010 were selected. Patients were followed for 1 year after their first observed T2DM diagnosis; patients
not continuously enrolled during this period were excluded from the study. Study measures included annual health
care expenditures by component (i.e., inpatient, outpatient, pharmacy, total). Patients accruing total costs in the top
10% of the overall cost distribution (i.e., patients with costs > $20,528) were classified as HC a priori; all other patients
were considered NHC. To assess predictors of being HC, a logistic regression model was estimated, accounting for
demographics; underlying comorbidity burden (using the Charlson Comorbidity Index [CCI] score); diagnoses of renal
impairment, obesity, or hypertension; and receipt of insulin, oral antidiabetics only, or no antidiabetics.
Results: A total of 1,720,041 patients met the inclusion criteria; 172,004 were HC. The mean (SD) CCI score for HC
patients was 4.3 (3.0) versus 2.1 (1.7) for NHC patients. Mean (SD; upper 95% confidence interval-lower 95% confidence
interval) annual per-patient costs were $56,468 ($65,604; $56,778-$56,157) among HC patients and $4,674 ($4,504;
$4,695-$4,652) among NHC patients. Inpatient care and pharmacy costs were higher for HC patients than for NHC
patients. The strongest predictor of being an HC patient was having a CCI score of 2 or greater (odds ratio
[OR] = 4.896), followed by a diagnosis of obesity (OR = 2.106), renal impairment (OR = 2.368), and insulin use
(OR = 2.098).
Conclusions: High-cost T2DM patients accrue approximately $52,000 more in total annual health care costs than not
high-cost T2DM patients. Patients were significantly more likely to be high-cost if they had comorbid conditions, a
diagnosis of obesity, or used insulin.
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Diabetes is a chronic, progressive condition that, if not
managed properly, can lead to numerous health complica-
tions and disability. It has been estimated that approxi-
mately 25.8 million people in the United States (US) have
diabetes [1]. In adults, 90% to 95% of patients with dia-
betes have type 2 diabetes mellitus (T2DM), which is
characterized by insulin resistance, pancreatic beta-cell* Correspondence: jmeyers@rti.org
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reproduction in any medium, provided the ordysfunction, and excessive glucose production by the liver.
Over the next 40 years, the total prevalence of diabetes in
the US is expected to more than double, from 5.6% in
2005 to 12.0% in 2050 [2].
Treatment of T2DM consists of significant lifestyle
adjustments and drug therapy, including oral antidia-
betic agents and insulin therapy [3]. The American
Diabetes Association and the European Association for
the Study of Diabetes have agreed that early interven-
tion with metformin should be used in patients with
hyperglycemia to help maintain recommended levels of
glycemic control [4]. Because T2DM is a progressiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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agents, such as insulin, sulfonylureas, thiazolidinediones,
dipeptidyl peptidase-4 inhibitors, and glucagon like
peptide-1 receptor agonists, also is recommended [5].
It is well established that the costs attributable to dia-
betes (including T2DM) are substantial. One recent esti-
mate suggested that the total economic burden of all
types of diabetes in the US exceeds $174 billion annually,
which includes $116 billion in excess medical expendi-
tures and $58 billion in reduced nation productivity [6].
Medical costs attributed to all types of diabetes include
$27 billion for direct care, $58 billion to treat patients with
diabetes-related chronic complications, and $31 billion in
excess general medical costs [6].
Significant evidence exists showing the relationship
between diabetes-related costs and observed glucose
values [7-12]. However, as informative as these studies
have been in communicating the economic impact of
diabetes, many studies have included data from sources
outside the US or did not focus on managed care popu-
lations. Further, identifying T2DM patients who could
be considered high cost (HC) is of significant interest to
health care payers, given the rising health care costs in
the US—interventions could be developed that would
focus on patients who are likely to become HC and
therefore minimize costs of the disease. Previous studies
have identified HC patients in other disease areas (e.g.,
acute coronary syndromes) [13]; but to our knowledge,
no retrospective analysis has been published that exam-
ines HC patients with T2DM.
The goal of this analysis was to document the actual
health care costs incurred by payers for a T2DM popula-
tion and to determine which factors were associated
with patients in the higher tiers of the T2DM cost distri-
bution. Additionally, this study compared health care
costs for patients who were identified as HC with pa-
tients who were identified as not high cost (NHC).
Methods
This analysis used the LifeLink database (formerly Phar-
Metrics), a commercially available source of computer-
ized administrative claims from 95 managed care health
plans covering more than 61 million unique patients.
The database included claims from private health plans
in all four US geographic regions and had an age and
sex distribution representative of national managed care
enrollment. The database included patient-level demo-
graphics and periods of health plan enrollment; primary
and nonprimary diagnoses; detailed information about
hospitalizations, diagnostic testing, and therapeutic pro-
cedures; inpatient and outpatient physician services;
prescription drug use; and cost data in the form of
managed-care reimbursement rates for each service.
Data are tracked longitudinally within patients viade-identified and unique patient numbers. For the pur-
poses of this analysis, the most recent 5 years of data
were used. RTI International’s institutional review board
determined that this study met all criteria for exemp-
tion. Data were available from January 1, 2005, through
December 31, 2010.
All patients with at least two diagnoses of T2DM
(International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] codes 250.×0 and
250.×2) during the selection window (January 1, 2005,
through December 31, 2009) were initially identified for
study inclusion. Requiring two T2DM diagnoses helped
to rule out patients who may have been suspected of
having T2DM but were never formally diagnosed and
likely eliminated patients who were miscoded as having
T2DM. For each patient identified, his or her index date
was defined as the date of the first observed T2DM diag-
nosis. To allow for adequate follow-up time to address
the research questions and to ensure that any observed
lack of health care events was the result of no medical
activity and not the result of cessation of care, patients
were required to have at least 12 months of continuous
post-index date observation. Furthermore, to obtain the
largest possible sample size of patients with T2DM, we did
not require patients to have received a diabetic medica-
tion, nor was any pre-index date enrollment required.
Subgroups of patients in the T2DM population were
identified as HC or NHC on the basis of where their an-
nual costs fell within the overall T2DM cost distribution.
We identified two subgroups of HC T2DM patients a
priori: those patients whose costs were in the 90th or
greater percentile of all-cause costs and those patients
whose costs were in the 80th or greater percentile of all-
cause costs. We also identified two subgroups of NHC
T2DM patients: those patients whose costs were below
the 90th percentile of all-cause costs and those patients
whose costs were below the 80th percentile of all-cause
costs. We chose to assess both the top 10% and top 20%
of patients in the all-cause cost distribution for several rea-
sons. First, it is a well-regarded rule of thumb that the top
20% of patients accrue 80% of health care costs [14]. We
wished to evaluate whether this rule held true in a T2DM
population. Second, previous studies examining HC pa-
tients in other disease areas have used similar method-
ology [13]. We also felt that it was important to see if
patient characteristics changed as we went from the top
20% of patients to the top 10% of patients. For this analysis
examining HC and NHC T2DM patients, all-cause costs
were examined (rather than T2DM-related costs) because
many patients likely had coexisting conditions (e.g., hyper-
tension or renal impairment) that were T2DM related but
that may not have been coded as such in the claims.
HC patients then were compared with NHC patients.
Key outcome measures that were analyzed included
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source use and costs, and T2DM-related resource use
and costs. All outcome measures presented in this paper
were assessed over a 1-year post-index date follow-up
period, unless stated otherwise. Patient characteristics that
were assessed at the index date included age, sex, geo-
graphic region, insurance payer type (i.e., commercial,
Medicare, Medicaid, self, Medicare Gap, and missing/un-
known), and health plan type (i.e., health maintenance
organization, preferred provider organization, point of ser-
vice, indemnity, and missing/unknown). To assess overall
comorbidity burden, we calculated a Charlson Comorbid-
ity Index (CCI) score for each patient over the 1-year
follow-up period. The mean CCI score, along with the
number and percentage of patients with a score < 2 or ≥ 2,
was reported. The CCI score included 17 categories of co-
morbidities, as defined by ICD-9-CM diagnosis and pro-
cedure codes, with associated weights corresponding to
the severity of the comorbid condition of interest [15].
Because all patients in the study had a diagnosis of
T2DM and because we wished to evaluate underlying
comorbidity burden independent of T2DM, comorbidi-
ties corresponding to T2DM were removed from the
CCI score (i.e., we did not want the CCI to be inflated
for all patients). Antidiabetic agents received were re-
ported by class (i.e., sulfonylureas, meglitinide, biguanide,
thiazolidinedione, alpha-glucosidase inhibitor, dipeptidyl
peptidase-4, glucagon-like peptide-1, and insulin).
For each patient, overall health care utilization and as-
sociated costs were aggregated across all encounters,
regardless of reason, observed during the 1-year post-
index date period. The following categories of overall
health care utilization and costs were evaluated and re-
ported: inpatient, skilled nursing facility, emergency
department, outpatient hospital, office visit, laboratory
service, other outpatient care, pharmacy, and total health
care utilization. For each category of overall health care
utilization, the number and percentage of patients with a
visit or admission, the mean (standard deviation [SD])
number of visits or admissions, and the per-patient costs
were reported. Additionally, for patients with an in-
patient or skilled nursing facility admission, the average
number of days per admission was reported.
The total volume and associated costs of health care
services specifically related to T2DM also was reported.
Hospital admissions related to T2DM were identified by
searching for inpatient hospital confinements in which
T2DM was recorded as the primary discharge diagnosis
(i.e., ICD-9-CM codes 250.×0 and 250.×2). Office, emer-
gency department, outpatient hospital, other outpatient
visits, and laboratory services related to T2DM were
identified by searching for medical claims with any diag-
nosis (i.e., primary or secondary) of T2DM and a rele-
vant place-of-service code for the care setting of interest.Additionally, we evaluated the use and associated costs
of all disease-specific medications for which a claim was
generated. Medications were identified using appropriate
National Drug Codes and Healthcare Common Proced-
ure Coding System codes, brand and generic product
names, and therapeutic class descriptions provided in
the database.
All analyses were carried out using SAS (Version 9;
Cary, North Carolina) statistical software. Descriptive
analyses entailed the tabular display of mean and SDs
for continuous variables of interest (e.g., total health care
costs) and the frequency distribution of categorical vari-
ables of interest (e.g., health plan type). All-cause and
diabetes-related health care costs were updated to 2011
US dollars, using the medical care component of the US
Consumer Price Index.
Logistic regression models were estimated to assess
predictors of being an HC patient with T2DM (separate
models for the top-10% and the top-20% groups). The
dependent variable was a dichotomous (i.e., 0 or 1) vari-
able indicating whether the patient was in the HC co-
hort. Demographic characteristics that have repeatedly
been shown to be associated with costs were used as inde-
pendent variables and included patient age (i.e., < 35 years,
35–44 years, and 45–54 years vs. ≥ 55 years), sex (i.e.,
male vs. female), geographic region (i.e., South, Midwest,
and West vs. East), health plan type (i.e., preferred pro-
vider organization, point of service, indemnity, and miss-
ing/unknown vs. health maintenance organization), and
payer type (i.e., Medicaid, Medicare, self, Medicare Gap,
and missing/unknown vs. commercial). Clinical variables
available in the database were also selected as independent
variables and included the CCI score (i.e., CCI score < 2
vs. CCI score ≥ 2), the types of pharmacologic treatments
the patient received (i.e., insulin and oral antidiabetic
medications vs. no pharmacological treatment), a diagno-
sis of renal impairment (i.e., had a renal impairment diag-
nosis vs. did not have a renal impairment diagnosis), and a
diagnosis of obesity (i.e., had an obesity diagnosis vs. did
not have an obesity diagnosis). Patients with missing age,
sex, health plan, and health payer information were ex-
cluded from the regression models.
Results
Among the 1.72 million T2DM patients in the database
who met the initial study inclusion and exclusion cri-
teria, 344,019 were identified as being in the top 20% of
the cost distribution (i.e., costs > $10,901), and 172,004
were identified as being in the top 10% of the cost distri-
bution (i.e., costs > $20,528) (Table 1). Mean (SD) patient
age among patients in the top 20% of the cost distribu-
tion was 57.2 (13.7) years versus 57.7 (14.9) years among
patients in the bottom 80% of the cost distribution. In
both the top 20% and the bottom 80% of patients, sex
Table 1 Characteristics of the study sample, by cohort
Cohort
Top 10% of costs Bottom 90% of costs Top 20% of costs Bottom 80% of costs
N % N % N % N %
Total sample 172,004 1,548,037 344,019 1,376,022
Age (years)
< 18 1,194 0.69% 17,232 1.11% 3,469 1.01% 14,957 1.09%
18-25 1,445 0.84% 17,163 1.11% 3,269 0.95% 15,339 1.11%
25-34 4,920 2.86% 56,918 3.68% 11,866 3.45% 49,972 3.63%
35-44 14,922 8.68% 164,584 10.63% 31,878 9.27% 147,628 10.73%
45-54 40,506 23.55% 359,704 23.24% 80,397 23.37% 319,813 23.24%
55-64 69,775 40.57% 474,253 30.64% 130,935 38.06% 413,093 30.02%
≥ 65 39,168 22.77% 457,026 29.52% 82,028 23.84% 414,166 30.10%
Missing/unknown 74 0.04% 1,157 0.07% 177 0.05% 1,054 0.08%
Mean (SD) 57.46 (12.89) 57.61 (14.82) 57.17 (13.66) 57.7 (14.87)
Sex
Male 86,359 50.21% 789,524 51% 164,587 47.84% 711,296 51.69%
Female 85,630 49.78% 758,425 48.99% 179,402 52.15% 664,653 48.30%
Missing/unknown 15 0.01% 88 0.01% 30 0.01% 73 0.01%
Geographic region
East 55,618 32.34% 521,500 33.69% 113,485 32.99% 463,633 33.69%
South 36,130 21.01% 371,487 24% 71,733 20.85% 335,884 24.41%
Midwest 55,462 32.24% 444,249 28.70% 110,809 32.21% 388,902 28.26%
West 24,794 14.41% 210,801 13.62% 47,992 13.95% 187,603 13.63%
Health plan type
Health maintenance organization 37,332 21.70% 293,868 18.98% 73,580 21.39% 257,620 18.72%
Preferred provider organization 96,019 55.82% 873,018 56.40% 190,440 55.36% 778,597 56.58%
Point of service 23,776 13.82% 178,510 11.53% 45,378 13.19% 156,908 11.40%
Indemnity 13,218 7.68% 181,335 11.71% 31,063 9.03% 163,490 11.88%
Missing/unknown 1,659 0.96% 21,306 1.38% 3,558 1.03% 19,407 1.41%
Payer type
Commercial 125,980 73.24% 1,156,587 74.71% 253,795 73.77% 1,028,772 74.76%
Medicaid 3,154 1.83% 17,382 1.12% 6,019 1.75% 14,517 1.05%
Medicare 18,213 10.59% 91,170 5.89% 31,044 9.02% 78,339 5.69%
Self 19,946 11.60% 213,595 13.80% 42,432 12.33% 191,109 13.89%
Medicare Gap 3,987 2.32% 60,944 3.94% 9,317 2.71% 55,614 4.04%
Missing/unknown 724 0.42% 8,359 0.54% 1,412 0.41% 7,671 0.56%
CCI Scorea
Mean (SD) 4.27 (3.04) 2.07 (1.68) 3.66 (2.75) 1.95 (1.55)
CCI < 2 32,217 18.73% 879,610 56.82% 88,195 25.64% 823,632 59.86
CCI≥ 2 139,787 81.27% 668,427 43.18% 255,824 74.36% 552,390 40.14
Charlson comorbidities
Myocardial infarction 20,594 11.97% 32,411 2.09% 29,040 8.44% 23,965 1.74%
Congestive heart failure 36,022 20.94% 84,121 5.43% 55,756 16.21% 64,387 4.68%
Peripheral vascular disease 21,069 12.25% 68,687 4.44% 34,510 10.03% 55,246 4.01%
Cardiovascular disease 31,358 18.23% 109,220 7.06% 53,770 15.63% 86,808 6.31%
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Table 1 Characteristics of the study sample, by cohort (Continued)
Dementia 2,419 1.41% 11,390 0.74% 4,765 1.39% 9,044 0.66%
Chronic pulmonary disease 49,776 28.94% 213,749 13.81% 89,955 26.15% 173,570 12.61%
Rheumatological disease 8,821 5.13% 30,566 1.97% 15,119 4.39% 24,268 1.76%
Peptic ulcer disease 5,174 3.01% 13,678 0.88% 8,643 2.51% 10,209 0.74%
Mild liver disease 3,654 2.12% 6,305 0.41% 5,380 1.56% 4,579 0.33%
Diabetes without chronic complications 169,829 98.74% 1,525,023 98.51% 339,677 98.74% 1,355,175 98.48%
Diabetes with chronic complications 45,140 26.24% 219,433 14.17% 83,992 24.41% 180,581 13.12%
Paraplegia 3,765 2.19% 4,538 0.29% 5,139 1.49% 3,164 0.23%
Renal impairment 17,789 10.34% 29,344 1.90% 26,180 7.61% 20,953 1.52%
Cancer 34,466 20.04% 101,118 6.53% 54,085 15.72% 81,499 5.92%
Severe liver disease 39,130 22.75% 113,367 7.32% 66,117 19.22% 86,380 6.28%
Metastatic cancer 9,830 5.71% 7,726 0.50% 12,346 3.59% 5,210 0.38%
HIV/AIDS 1,094 0.64% 2,050 0.13% 1,693 0.49% 1,451 0.11%
Antidiabetic agents received on Index
Glucagon-like peptide-1 991 0.58% 7,500 0.48% 2,390 0.69% 6,101 0.44%
Dipeptidyl peptidase-4 629 0.37% 6,071 0.39% 1,291 0.38% 5,409 0.39%
Biguanides 21,285 12.37% 218,752 14.13% 46,060 13.39% 193,977 14.10%
Sulfonylureas 14,169 8.24% 122,570 7.92% 29,290 8.51% 107,449 7.81%
Thiazolidinedione 9,976 5.80% 85,809 5.54% 23,079 6.71% 72,706 5.28%
Meglitinides 1,045 0.61% 7,266 0.47% 2,491 0.72% 5,820 0.42%
Alpha-glucosidase inhibitors 187 0.11% 1,435 0.09% 460 0.13% 1,162 0.08%
Insulin 14,220 8.27% 70,542 4.56% 29,921 8.70% 54,841 3.99%
Other antidiabetic agents 8,689 5.05% 79,749 5.15% 19,045 5.54% 69,393 5.04%
CCI = Charlson Comorbidity Index; SD = standard deviation.
aCCI score calculated in the 1-year post-index date period.
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CCI score was greater among patients in the top 20% of
the cost distribution (3.7 [2.8]), than among patients in
the bottom 80% of the cost distribution (2.0 [1.6]).
Chronic pulmonary disease, liver disease, and congestive
heart failure were the most common conditions in both
cohorts. The percentage of patients receiving oral antidi-
abetic medications at index date was approximately the
same in both cohorts; however, more than twice the
percentage of patients in the top 20% of the cost distri-
bution received insulin, compared with patients in the
bottom 80% of the cost distribution (8.7% vs. 4.0%).
Patients in the top 10% of the cost distribution were
found to be similar to patients in the top 20% of the cost
distribution in terms of mean age, sex distribution, geo-
graphic region, health plan type, and payer type. The
mean (SD) CCI score was greater for patients in the top
10% of the cost distribution (4.3 [3.0]), with a greater per-
centage of these patients having nearly all of the individual
CCI components, than for patients in the top 20% of the
cost distribution (2.1 [1.7]). Additionally, approximately
the same percentage of patients in the top 10% of the costdistribution received oral antidiabetic medications and in-
sulin as in the top 20% of the cost distribution.
The strongest predictor of being an HC patient (either in
the top 20% or top 10% of the cost distribution) was having
a CCI score ≥ 2 (odds ratio [OR] for top 20% regression vs.
top 10% regression: 3.9 vs. 4.9; both P < 0.0001) (Table 2).
Additionally, a diagnosis of renal impairment (OR for top
20% regression vs. top 10% regression: 2.2 vs. 2.4; both
P < 0.0001), a diagnosis of obesity (OR for top 20% regres-
sion vs. top 10% regression: 2.0 vs. 2.1; both P < 0.0001), re-
ceipt of insulin (OR for top 20% regression vs. top 10%
regression: 2.7 vs. 2.1; both P < 0.0001), and a diagnosis of
hypertension (OR for top 20% regression vs. top 10% re-
gression: 1.5 vs. 1.6; both P < 0.0001) were all found to be
associated with a significant increase in the odds of being
an HC patient.
Patients in the top 20% of the cost distribution had
total all-cause costs that were, on average, $32,179 more
than the costs accrued by patients in the bottom 80% of
the cost distribution (mean [SD] all-cause costs, top 20%
vs. bottom 80%: $35,596 [$50,903] vs. $3,417 [$2,775])
(Table 3). Furthermore, patients in the top 10% of the
Table 2 Predictors of being an HC T2DM patient, among all patients with T2DMa
Variable Cohort
Top 10% of all-cause costs Top 20% of all-cause costs
Odds ratio Lower 95% CI Upper 95% CI P value Odds ratio Lower 95% CI Upper 95% CI P value
Age, in years (vs. 55+ years)
< 35 1.128 1.098 1.159 < 0.0001 1.311 1.286 1.337 < 0.0001
35-44 1.063 1.043 1.085 < 0.0001 1.094 1.078 1.110 < 0.0001
45-54 1.200 1.184 1.216 < 0.0001 1.179 1.167 1.191 < 0.0001
Female (vs. male) 1.023 1.012 1.034 < 0.0001 1.175 1.165 1.184 < 0.0001
Geographic region (vs. East)
South 0.814 0.800 0.827 < 0.0001 0.763 0.754 0.773 < 0.0001
Midwest 1.166 1.150 1.183 < 0.0001 1.156 1.144 1.168 < 0.0001
West 1.107 1.088 1.128 < 0.0001 1.047 1.033 1.062 < 0.0001
Health plan type (vs. health
maintenance organization)
Preferred provider organization 1.091 1.074 1.108 < 0.0001 1.041 1.029 1.054 < 0.0001
Point of service 1.141 1.119 1.163 < 0.0001 1.080 1.063 1.096 < 0.0001
Indemnity 0.510 0.499 0.521 < 0.0001 0.608 0.598 0.618 < 0.0001
Payer type (vs. commercial)
Medicaid 1.221 1.170 1.274 < 0.0001 1.198 1.157 1.239 < 0.0001
Medicare or Medicare Gap 1.070 1.050 1.089 < 0.0001 0.978 0.964 0.992 0.0024
Self 0.885 0.868 0.902 < 0.0001 0.967 0.953 0.981 < 0.0001
Charlson Comorbidity Index
score≥ 2 (vs. < 2)
4.896 4.832 4.961 < 0.0001 3.908 3.873 3.944 < 0.0001
Renal impairment diagnosis
(vs. no renal impairment diagnosis)
2.368 2.333 2.404 < 0.0001 2.179 2.150 2.208 < 0.0001
Hypertension diagnosis
(vs. no hypertension diagnosis)
1.625 1.602 1.648 < 0.0001 1.519 1.504 1.535 < 0.0001
Obesity diagnosis
(vs. no obesity diagnosis)
2.106 2.076 2.13741 < 0.0001 2.033 2.009 2.056 < 0.0001
Antidiabetic treatment
(vs. no treatment)
Received insulin 2.098 2.068 2.128 < 0.0001 2.744 2.7142 2.775 < 0.0001
Received oral antidiabetic
agents only
1.110 1.097 1.124 < 0.0001 1.283 1.271 1.294 < 0.0001
CI = confidence interval; HC = high cost; T2DM = type 2 diabetes mellitus.
a28,100 patients were excluded from the regression analysis because they were missing age, sex, health plan, or payer information.
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average, $51,794 more than the costs accrued by patients
in the bottom 90% of the cost distribution (i.e., mean
[SD] all-cause costs, top 10% vs. bottom 90%: $56,468
[$65,604] vs. $4,674 [$4,504]. Additionally, all-cause costs
for patients in the top 10% of the cost distribution were
approximately $20,872 more than all-cause costs for pa-
tients in the top 20% of the cost distribution.
All-cause inpatient visits were responsible for ap-
proximately 42% of the difference in all-cause costs be-
tween patients in the top 20% and patients in the
bottom 80% of the cost distribution, with 55.8% of pa-
tients in the top 20% of the cost distribution having atleast one all-cause hospitalization and 21.0% of patients
having two or more hospitalizations compared with
7.4% of patients in the bottom 80% of the cost distribu-
tion having at least one all-cause hospitalization and
1.3% of patients having two or more hospitalizations.
Similarly, all-cause inpatient visits were responsible for
approximately 47% of the difference in costs between
patients in the top 10% and patients in the bottom 90%
of the distribution, with 74.2% of patients in the top
10% of the distribution having at least one all-cause
hospitalization and 34.4% of patients having two or
more hospitalizations, compared with only 10.8% of pa-
tients in the bottom 90% of the distribution having at
Table 3 Summary of overall health care utilization and costs during the 12-month follow-up period, by cohort
Cohort
Top 10% of costs Bottom 90% of costs Top 20% of costs Bottom 80% of costs
Inpatient services
Had≥ 1 hospital admission (n, %) 127,553 74.16% 166,729 10.77% 192,070 55.83% 102,212 7.43%
Had≥ 2 hospital admissions (n, %) 59,199 34.42% 31,289 2.02% 72,263 21.01% 18,225 1.32%
Mean number of admissions (SD) 1.44 (1.62) 0.14 (0.45) 0.97 (1.36) 0.09 (0.37)
Mean (SD) inpatient daysa 13.81 (24.88) 7.07 (39.57) 11.65 (22.04) 6.89 (49.31)
Mean (SD) total costs $24,766 ($48,149) $427 ($1,739) $13,618 ($35,945) $171 ($805)
SNF stays
Had≥ 1 SNF admission (n, %) 10,410 6.05% 8,987 0.58% 14,047 4.08% 5,350 0.39%
Mean number of SNF admissions (SD) 0.10 (0.49) 0.01 (0.14) 0.07 (0.41) 0.01 (0.10)
Mean (SD) SNF daysa 33.70 (44.70) 48.52 (203.18) 42.75 (135.81) 34.84 (157.98)
Mean (SD) total costs $525 ($3,532) $20 ($389) $323 ($2,612) $7 ($180)
ED visits
Had≥ 1 ED visit (n, %) 103,348 60.08% 355,475 22.96% 183,931 53.47% 274,892 19.98%
Mean number of ED visits (SD) 5.31 (14.32) 1.29 (4.60) 4.26 (11.65) 1.05 (3.90)
Mean (SD) total costs $888 ($2,283) $136 ($505) $659 ($1,791) $99 ($370)
Office visits
Had≥ 1 office visit (n, %) 168,403 97.91% 1,505,071 97.22% 336,935 97.94% 1,336,539 97.13%
Mean number of office visits (SD) 26.00 (20.97) 12.72 (12.11) 23.73 (19.25) 11.62 (10.86)
Mean (SD) total costs $5,827 ($13,092) $1,155 ($1,440) $4,246 ($9,562) $967 ($1,098)
Pharmacy
Had≥ 1 prescription (n, %) 150,474 87.48% 1,225,785 79.18% 302,929 88.06% 1,073,330 78.00%
Mean number of prescriptions (SD) 53.72 (44.11) 27.99 (28.83) 50.37 (41.21) 25.61 (26.56)
Mean (SD) total costs $4,854 ($12,486) $1,428 ($2,162) $4,190 ($9,270) $1,166 ($1,660)
Outpatient hospital visits
Had≥ 1 outpatient visit (n, %) 131,885 76.68% 844,910 54.58% 257,619 74.89% 719,176 52.26%
Mean number of outpatient visits (SD) 43.33 (82.58) 9.15 (20.37) 32.64 (65.27) 7.55 (16.13)
Mean (SD) total costs $8,763 ($22,823) $767 ($1,816) $5,807 ($16,625) $507 ($1,136)
Laboratory services
Had≥ 1 laboratory service (n, %) 92,529 53.79% 655,781 42.36% 178,840 51.99% 569,470 41.39%
Mean number of laboratory services (SD) 13.13 (30.85) 5.50 (11.32) 10.72 (24.64) 5.15 (10.57)
Mean (SD) total costs $247 ($810) $75 ($210) $194 ($630) $66 ($179)
OOP services
Had≥ 1 OOP services (n, %) 153,936 89.50% 834,883 53.93% 293,499 85.31% 695,320 50.53%
Mean number of OOP services (SD) 46.30 (95.37) 8.49 (22.41) 34.05 (75.59) 6.82 (16.91)
Mean (SD) total costs $10,598 ($29,858) $666 ($1,633) $6,559 ($21,633) $434 ($1,016)
Total health care utilization
Had≥ 1 medical encounter (n, %) 172,004 100.00% 1,548,037 100.00% 344,019 100.00% 1,376,022 100.00%
Mean number of encounters (SD) 189.33 (150.55) 65.29 (51.82) 156.81 (123.32) 57.92 (42.74)
Mean (SD) total costs $56,468 ($65,604) $4,674 ($4,504) $35,596 ($50,903) $3,417 ($2,775)
ED = emergency department; OOP = other outpatient; SD = standard deviation; SNF = skilled nursing facility.
aMean inpatient and SNF days estimated among only those patients with at least 1 unique admission.
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having two or more hospitalizations.
All-cause outpatient hospital visits contributed to ap-
proximately 16.5% of the difference in costs between pa-
tients in the top 20% and patients in the bottom 80% of
the cost distribution, with 74.9% of patients in the top
20% of the cost distribution having at least one all-cause
outpatient hospital visit compared with 52.3% of patients
in the bottom 80% of the cost distribution. Outpatient
hospital visits had a similar contribution to the differ-
ence in costs between patients in the top 10% and
patients in the bottom 90% of the cost distribution. Spe-
cifically, all-cause outpatient hospital visits contributed
to approximately 15.4% of the difference in all-cause
costs between patients in the top 10% of the cost distri-
bution and patients in the bottom 90% of the cost distri-
bution, with 76.7% of patients in the top 10% of the cost
distribution having at least one all-cause outpatient hos-
pital visit, compared with 54.6% of patients in the bot-
tom 90% of the all-cause cost distribution.
All-cause prescription fills and all-cause office visits
contributed to 9.4% and 10.2% of the difference in all-
cause costs among patients in the top 20% and bottom
80%, respectively, of the cost distribution. All-cause pre-
scription fills and all-cause office visits contributed to
6.6% and 9.0% of the difference among patients in the
top 10% and bottom 90%, respectively, of the cost distri-
bution. However, patients in both the top 20% and top
10% of the cost distribution filled approximately twice as
many prescriptions and had almost double the number
of physician office visits, compared with patients in the
bottom 80% and bottom 90% of the cost distribution
(top 20% vs. bottom 80%: 50.4 vs. 25.6 prescription fills;
23.7 vs. 11.6 office visits: top 10% vs. bottom 90%: 53.7
vs. 28.0 prescription fills; 26.0 vs. 12.7 office visits).
Health care costs related to T2DM were, on average,
$2,977 more for patients in the top 20% of the cost dis-
tribution than for patients in the bottom 80% of the cost
distribution and $4,136 more for patients in the top 10%
of the cost distribution than for patients in the bottom
90% of the cost distribution (Table 4). Mean (SD) T2DM-
related costs among patients in the top 20% of the cost dis-
tribution were $3,780 ($8,530), which represented 10.6% of
all-cause costs; T2DM-related costs among patients in the
bottom 80% of the cost distribution were $803 ($1,065),
which represented 23.5% of all-cause costs. Similarly, mean
(SD) T2DM-related costs among patients in the top 10% of
the cost distribution were $5,121 ($11,575), which repre-
sented 9.1% of all-cause costs; T2DM-related costs among
patients in the bottom 90% of the cost distribution were
$985 ($1,469), which represented 21.1% of all-cause costs.
Unlike all-cause costs, the biggest difference in T2DM-
related costs between patients in the top 20% and 10% and
patients in bottom 80% and 90% of the cost distributionwas outpatient hospital visits, which accounted for ap-
proximately 25% of the cost difference in both groups.
The entire T2DM population included in this study
(N = 1,720,041) accrued all-cause costs of approximately
$17 billion (Figures 1 and 2). The top 10% of patients ac-
crued costs of more than $9.7 billion, which represented
more than 57% of the costs accrued by this population.
The top 20% of patients accrued costs of more than $12
billion, which represented more than 72% of the costs
accrued by this population. In the overall population of
patients, over $2.4 billion of the total all-cause costs could
be directly linked to T2DM (i.e., 14.2% of all-cause costs
accrued by this population were attributable directly to
T2DM). The top 10% of patients accrued T2DM-related
costs of $880 million, which represented 36.6% of the total
T2DM-related costs, while the top 20% of patients ac-
crued T2DM-related costs of $1.3 billion, which repre-
sented 54.1% of the total T2DM-related costs.
Discussion
This study examined patients with T2DM in a large,
managed care population and quantified differences in
health care costs by categories of cost distributions. Pa-
tients were identified as being HC if their total care costs
fell in the top 10% or the top 20% of the total cost distri-
bution. Patients in the top 10% of the total cost distribu-
tion accrued annual per-patient health care costs that
were on average $50,000 more than the annual per-
patient health care costs accrued by patients in the bot-
tom 90% of the total cost distribution. Similarly, patients
in the top 20% of the total cost distribution accrued an-
nual per-patient health care costs that were over $32,000
more than the annual per-patient health care costs ac-
crued by patients in the bottom 80% of the total cost dis-
tribution. Multivariable logistic regression models found
that patients were significantly more likely to be in the top
10% or the top 20% of the total cost distribution if they
had a CCI score ≥ 2; had received a diagnosis of renal
impairment, obesity, or hypertension; or were treated
with insulin.
Data drawn from the Medical Expenditure Panel Sur-
vey have previously shown that a small percentage of pa-
tients typically account for a large percentage of health
care costs. Specifically, using data from 1999, the survey
found that, in the general community population, more
than half of the total health care spending was accrued
by only 5% of the population [16]. The Olin study sup-
ports the rule of thumb that 20% of patients consume
80% of health care resources. Additionally, Conwell and
Cohen, using data from a 2002 US noninstitutionalized
population, found that exactly 20% of patients accrued
80% of costs [14]. Similarly, we found that patients in
the top 20% of the total cost distribution accrued costs
of $12.2 billion annually, which represented 72% of the
Table 4 Summary of diabetes-related health care utilization and costs during the 12-month follow-up period, by
cohort
Cohort
Top 10% of costs Bottom 90% of costs Top 20% of costs Bottom 80% of costs
Diabetes-related inpatient stays
Had≥ 1 hospital admission (n, %) 30,310 17.62% 27,729 1.79% 41,220 11.98% 16,819 1.22%
Mean number of hospital admissions (SD) 0.23 (0.60) 0.02 (0.15) 0.15 (0.48) 0.01 (0.12)
Mean (SD) inpatient daysa 6.93 (10.48) 4.29 (7.60) 6.28 (9.68) 4.17 (8.16)
Mean costs (SD) $677 ($5,515) $20 ($331) $387 ($3,953) $10 ($194)
Diabetes-related SNF stays (n, %)
Had≥ 1 SNF admission 1,802 1.05% 1,405 0.09% 2,468 0.72% 739 0.05%
Mean number of SNF admissions (SD) 0.01 (0.14) 0.00 (0.04) 0.01 (0.12) 0.00 (0.03)
Mean (SD) SNF daysa 12.96 (31.56) 22.29 (139.07) 17.53 (105.76) 15.41 (43.85)
Mean costs (SD) $14 ($424) $1 ($76) $9 ($332) $0 ($37)
Diabetes-related ED visits
Had≥ 1 ED visit (n, %) 39,813 23.15% 132,909 8.59% 70,699 20.55% 102,023 7.41%
Mean number of ED visits (SD) 1.36 (5.88) 0.38 (2.37) 1.14 (5.03) 0.31 (2.07)
Mean costs (SD) $232 ($1,003) $42 ($277) $182 ($825) $31 ($204)
Diabetes-related office visits
Had≥ 1 office visit (n, %) 137,104 79.71% 1,273,378 82.26% 277,094 80.55% 1,133,388 82.37%
Mean number of office visits (SD) 4.28 (4.59) 3.42 (3.32) 4.23 (4.39) 3.33 (3.18)
Mean costs (SD) $469 ($1,290) $245 ($357) $424 ($1,002) $228 ($314)
Diabetes-related pharmacy
Had≥ 1 prescription (n, %) 107,729 62.63% 818,451 52.87% 219,248 63.73% 706,932 51.38%
Mean number of prescriptions (SD) 6.98 (8.57) 5.49 (7.72) 7.29 (8.78) 5.22 (7.51)
Mean costs (SD) $636 ($1,660) $356 ($806) $702 ($1,511) $304 ($694)
Diabetes-related outpatient hospital visits
Had≥ 1outpatient visit (n, %) 69,070 40.16% 411,072 26.55% 131,277 38.16% 348,865 25.35%
Mean number of outpatient visits (SD) 6.18 (18.89) 2.46 (7.63) 5.23 (16.47) 2.23 (6.49)
Mean (SD) total costs $1,204 ($5,433) $145 ($652) $849 ($4,007) $101 ($408)
Diabetes-related laboratory services
Had≥ 1 laboratory service (n, %) 51,096 29.71% 439,858 28.41% 101,715 29.57% 389,239 28.29%
Mean number of laboratory services (SD) 3.52 (9.92) 2.76 (6.48) 3.35 (8.82) 2.71 (6.32)
Mean (SD) total costs $48 ($204) $29 ($90) $43 ($169) $28 ($85)
Diabetes-related OOP services
Had≥ 1 OOP service (n, %) 80,576 46.85% 414,844 26.80% 147,877 42.99% 347,543 25.26%
Mean number of OOP services (SD) 8.11 (24.22) 2.29 (7.32) 6.33 (19.66) 2.01 (6.09)
Mean costs (SD) $1,842 ($7,754) $147 ($659) $1,182 ($5,634) $100 ($398)
Diabetes-related total health care utilization
Had≥ 1 medical encounter (n, %) 168,326 97.86% 1,541,265 99.56% 338,383 98.36% 1,371,208 99.65%
Mean number of encounters (SD) 30.68 (37.16) 16.83 (16.26) 27.72 (31.67) 15.84 (14.58)
Mean costs (SD) $5,121 ($11,575) $985 ($1,469) $3,780 ($8,530) $803 ($1,065)
ED = emergency department; OOP = other outpatient; SD = standard deviation; SNF = skilled nursing facility.
aMean inpatient and SNF days estimated among only patients with at least 1 unique admission.
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Figure 1 Descriptive summary of all-cause health care costs during the 12-month follow-up period.
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ally, we found that patients in the top 10% of the total
cost distribution accrued costs of $9.7 billion annually,
which represented 57% of the total costs accrued by the
T2DM population.
This study used methodology similar to the approach
described by Etemad and McCollam in an article exam-
ining predictors of HC managed care patients with acute
coronary syndrome [13]. Etemad and McCollam identified
patients with newly onset acute coronary syndrome and
assessed these patients’ health care costs over 12 months
after disease onset. The authors classified patients as beingFigure 2 Descriptive summary of T2DM-related health care costs duriHC if the patients accrued costs in the top 20% of the
population; multivariable regression analyses were esti-
mated to assess predictors of being an HC patient. Similar
to our study, many of the factors associated with being an
HC patient in the Etemad analysis were nonmodifiable
comorbidities such as hypertension, diabetes, or pul-
monary disease.
Etemad and McCollam also observed that an initial
hospitalization for acute coronary syndrome had costs
that were equal to nearly two-thirds of the costs accrued
in the entire year following hospital discharge. Although
our study used a slightly different methodology (weng the 12-month follow-up period. T2DM = type 2 diabetes mellitus.
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stay) to that of Etemad and McCollam, we found that
approximately 40% of the health care costs accrued in
HC patients were associated with inpatient visits.
Hartmann [17] examined patients in the top decile of
health care spending, using German health insurance in-
formation. Consistent with our analysis, Hartmann found
that the highest health care expenses for patients were in-
curred in the inpatient sector, with over 80% of all HC pa-
tients having at least one hospital admission (compared
with 74.2% in our analysis) [17]. Additionally, Hartmann
[17] found that the reasons for the hospitalization differed
based on patient age and sex, which further highlights the
facts that HC patients require care tailored to their unique
situation and that no single intervention exists that will re-
duce health care costs among all patients.
A previous study examining Medicare patients with
T2DM found that interventions aimed at diabetes have
not differed based on comorbid illness burden [18]. Our
analysis found that patients with a higher comorbidity
burden and more concomitant conditions were signifi-
cantly more likely to be HC. Therefore, from the perspec-
tive of a payer, one practical implication of the present
analysis is that it may make sense to provide those pa-
tients who have the most comorbidities and concomitant
conditions (i.e., those patients who are at the greatest risk
of being HC) with additional patient care tailored at treat-
ing the comorbidity or concomitant condition (e.g., weight
loss programs for obese patients).
Sensitivity analyses were conducted, examining the
926,180 patients who received an antidiabetic medica-
tion (i.e., either an oral antidiabetic or insulin). In this
subpopulation of treated T2DM patients, those with
costs greater than $22,646 comprised the top 10th per-
centile (vs. $20,528 in the overall T2DM population),
while patients with costs greater than $12,349 comprised
the top 20th percentile (vs. $10,901 in the overall T2DM
population). We found that there were no differences in
patient demographics between the overall study sample
and those patients who received antidiabetic medication.
Predictors of being an HC T2DM patient were the same
for the treated and overall T2DM populations. Specifically,
in the treated T2DM population, having a CCI score
greater than or equal to 2 was the strongest predictor of
being an HC patient (OR = 4.862; P < 0.001), followed by a
renal impairment diagnosis (OR = 2.369; P < 0.001), an
obesity diagnosis (OR = 1.991; P < 0.001), or receipt of
insulin (OR = 1.897; P < 0.001). Treated patients in the top
10% of the cost distribution accrued approximately
$53,917 more in health care costs versus treated patients
in the bottom 90% of the cost distribution (vs. $51,794
more in costs in the overall T2DM population), with the
largest difference in costs attributable to inpatient stays.
Additionally, treated patients in the top 10% of the costdistribution accrued costs of over $5.5 billion, which rep-
resented 54.1% of all costs accrued by the treated T2DM
population (vs. 57.3% among all T2DM patients). Treated
patients in the top 20% of the cost distribution accrued
costs of over $7.0 billion, which represented 69.0% of all
costs accrued by the treated T2DM population (vs. 72.3%
among all T2DM patients).
This study has several limitations common to most
retrospective database studies. First, it was not possible
to confirm diagnoses for T2DM, renal impairment, hyper-
tension, or obesity. No laboratory data were available to
further assess the level of renal impairment, and no infor-
mation was available in the database regarding patients’
height or weight. Thus, rates of obesity and renal impair-
ment reported in the analysis are likely underestimated.
Additionally, no information was available regarding blood
glucose or glycated hemoglobin values, so the effect of
glucose control on costs could not be assessed. Logistic
regression model specifications were limited to the data
available, and additional predictors of being an HC patient
may exist (e.g., increased glycated hemoglobin value). Be-
cause this study used retrospective administrative claims,
it was not feasible to assess the effect of an intervention
(e.g., change in diabetes medication) on costs. Further, be-
cause our study used data from a managed care popula-
tion, results may not be applicable to Medicaid, Medicare,
or uninsured patients.
The goal of this study was to provide payers with a
means of identifying patients who are at increased risk
for becoming HC, using real-world data. Once these
patients are identified, personalized interventions could
be developed that may decrease the likelihood of the
patient becoming HC. Interventions might include
extra office visits for comorbid conditions, structured
weight loss programs, or increased pharmacotherapy for
glucose control. Economic evaluations to examine the
cost-benefit structure of developing such interventions
would be informative.
Conclusions
This study examined health care resource utilization and
costs in a large, real-world, managed care population. In
conclusion, it was found that patients with T2DM who
make up the top 10% of a cost distribution for T2DM
accrue, on average, 12 times more total annual health
care costs than patients who make up the bottom 90%
of the cost distribution. Further, T2DM patients who
make up the top 20% of the cost distribution accrue, on
average, 11 times more health care costs than patients
who make up the bottom 80% of the cost distribution.
Obesity and progression to insulin were found to predict
the odds of being an HC patient and are two modifiable
factors for T2DM patients. Further research is needed to
explore potential interventions to reduce the likelihood
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cost of a hospitalization was the largest component of
HC patients’ total care costs. Reducing all-cause hospitali-
zations in patients with T2DM through interventions
aimed at better management of T2DM (e.g., outpatient
management, lifestyle changes) may help to reduce costs.
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